Core Viewpoint - MicroPort Medical (0853.HK) is shifting from its previous strategy of spin-offs to focus on mergers and restructuring, specifically planning to merge its cardiac rhythm management business with its subsidiary, HeartLink Medical (2160.HK) [1][2]. Group 1: Merger Announcement - On July 17, MicroPort Medical announced the plan to merge its cardiac rhythm management business with HeartLink Medical, aiming to establish a cardiac product platform and share international marketing and sales channels [2]. - The merger proposal is currently non-binding and uncertain, with MicroPort Medical advising shareholders and potential investors to act cautiously when trading its securities [3]. Group 2: Financial Implications - Following the announcement, MicroPort Medical and HeartLink Medical saw stock price increases of 6.6% and 7.21%, respectively [4]. - If the merger proceeds successfully, HeartLink Medical's performance could significantly improve, as it currently faces challenges with a projected revenue of 362 million RMB and a net loss of 49 million RMB for 2024 [4]. - In contrast, MicroPort Medical's cardiac rhythm management business is already substantial, with expected revenue of 221 million USD (approximately 1.588 billion RMB) for 2024, and strong overseas market performance contributing over 80% of its revenue [4]. Group 3: Strategic Considerations - The integration of the cardiac rhythm management business into HeartLink Medical could enhance the latter's financial performance [5]. - The primary entity responsible for the cardiac rhythm management business is MicroPort Heart Rhythm Management Co., which had previously planned an IPO but has not progressed since May 2023 [6]. - The merger may be influenced by a contractual obligation to investors, as MicroPort Medical had agreed to redeem shares if the cardiac rhythm management business did not go public by July 17, 2025, with a market cap of at least 1.5 billion USD [7][8]. Group 4: Previous Transactions - This is not the first time HeartLink Medical has acquired assets from MicroPort Medical; in August of the previous year, it purchased real estate from MicroPort Medical for approximately 360 million RMB [9]. - The acquisition of significant assets by HeartLink Medical, which is not yet profitable and requires funding for research and development, raises questions about the feasibility and valuation of such transactions [10][11].